For Immediate Release
Chicago, IL – March 24, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (
ABT Quick Quote ABT - Free Report) , AstraZeneca PLC ( AZN Quick Quote AZN - Free Report) , Booking Holdings Inc. ( BKNG Quick Quote BKNG - Free Report) , Vertex Pharmaceuticals Incorporated ( VRTX Quick Quote VRTX - Free Report) and Yum China Holdings, Inc. ( YUMC Quick Quote YUMC - Free Report) . Here are highlights from Tuesday’s Analyst Blog: Top Analyst Reports for Abbott, AstraZeneca and Booking Holdings
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, AstraZeneca, and Booking Holdings. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> Abbott shares have outperformed the Zacks Medical Products industry over the past year (+74.5% vs. +47.1%). The Zacks analyst believes that the branded generics and international diabetes businesses should drive growth in the coming quarters. New product launches and acquisitions should boost sales further.
Moreover, its consumer-facing businesses like diabetes care, nutrition and established pharmaceuticals (EPD), are catching up pace. In Adult Nutrition, the company reported strong double-digit growth on robust sales of Ensure and Glucerna in the fourth quarter of 2020. Diabetes Care sales were strong on solid worldwide adoption of FreeStyle Libre.
In 2020, the company received U.S. approval of Freestyle Libre 2 and CE Mark for Libre 3 and Libre Sense Glucose Sport. Yet, the company’s performance was disappointing particularly in Pediatric Nutrition, Cardiovascular and Neuromodulation.
) read the full research report on Abbott here >>> AstraZeneca shares have lost -8.1% over the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +4.8%. The Zacks analyst believes that products like Nexium and Seroquel have been facing generic competition, which in turn is hurting sales.
The diabetes franchise also faces stiff competition while pricing pressure is hurting sales in the respiratory unit. Nonetheless, AstraZeneca’s newer drugs like Lynparza, Tagrisso and Imfinzi should keep driving revenues.
Its pipeline is strong with several phase III data readouts lined up for 2021. AstraZeneca has also engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like China.
) read the full research report on AstraZeneca here >>>
Booking Holdings have gained +2.5% in the past three months against the Zacks Internet Commerce industry’s gain of +1.9%. The Zacks analyst believes that Booking Holdings has been benefiting from improving bookings. The re-opening of the economy is contributing well to the company's bookings.
Additionally, its expanding payment platform is acting as a tailwind. The company remains optimistic about its highly variable cost structure and strong liquidity position, which are expected to help it in navigating through the current crisis scenario.
Moreover, growing alternative accommodation business and strengthening flight capabilities are other positives. However, disruptions in the travel industry caused by coronavirus remain major headwinds. Furthermore, continued sluggishness in the company's agency business remains an overhang.
) read the full research report on Booking Holdings here >>>
Other noteworthy reports we are featuring today include Vertex Pharmaceuticals and Yum China Holdings.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.